Clinical Trial Update: Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial comparing lasofoxifene to fulvestrant in advanced or metastatic ER+/HER2- breast cancer with ESR1 mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Lasofoxifene (Lasofoxifene)

Snippet

Sponsor: Sermonix Pharmaceuticals Inc. | Conditions: Locally Advanced or Metastatic Breast Cancer | Phase 2 | Status: COMPLETED